Balaji Gandhi - 25 Aug 2025 Form 4 Insider Report for Phreesia, Inc. (PHR)

Role
Chief Financial Officer
Signature
/s/ Allison Hoffman, as Attorney-in-Fact for Balaji Gandhi
Issuer symbol
PHR
Transactions as of
25 Aug 2025
Transactions value $
-$287,550
Form type
4
Filing time
27 Aug 2025, 16:16:28 UTC
Previous filing
21 Jul 2025
Next filing
15 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gandhi Balaji Chief Financial Officer C/O PHREESIA, 1521 CONCORD PIKE, SUITE 301 PMB 221, WILMINGTON /s/ Allison Hoffman, as Attorney-in-Fact for Balaji Gandhi 27 Aug 2025 0001970527

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHR Common Stock Sale -$288K -9.58K -8.98% $30.01 97.1K 25 Aug 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2024.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.